CervoMed reports Q2 loss $6.3M; neflamapimod shows 54% risk reduction in DLB extension phase

CervoMed Inc.

Net loss of $6.3M for Q2 2025 vs $2.3M loss a year ago; cash $33.5M as of June 30, 2025.
Phase 2b RewinD-LB extension: neflamapimod reduced risk of clinically significant worsening by 54% (p=0.0037) on CDR-SB at 32 weeks.
In patients with minimal AD co-pathology (ptau181<2.2), risk reduction improved to 64% (p=0.0001).
Significant decrease in plasma GFAP biomarker: -18.4 pg/mL from baseline in active group vs +1.1 pg/mL increase in placebo at Week 16.
Plans to meet FDA in Q4 2025 to align on Phase 3 trial design; Phase 3 initiation mid-2026 subject to funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.